Teresa Jurgensen

Teresa Jurgensen is the current SVP and General Counsel at 2seventy bio. Prior to this, they served as Vice President, General Counsel, Oncology at bluebird bio from December 2018 to January 2021. Teresa has also worked at Teva Pharmaceuticals as Senior Director, Associate General Counsel from October 2014 to November 2018. In this role, they were responsible for leading Teva's major acquisitions, divestments and collaborations. Teresa also served as a key member of the deal team, partnering with business development and providing strategic advice on legal and business matters.

Teresa Jurgensen has a J.D. from Widener University Commonwealth Law School and a J.D. from Widener University School of Law. Teresa also has a BS in marketing from Pennsylvania State University, University Park.

Teresa Jurgensen reports to Nick Leschly, Chief Kairos Officer. Some of their coworkers include Susan Abu - Absi - Chief Technology & Manufacturing Officer, Kevin Chin - Head of Clinical Development, and Chip Baird - Chief Financial Officer.